NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock Analysis

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BBOT

$2.68

−$0.04 (−1.47%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BBOT with… →

BBOT Key Statistics

As of Oct 21, 2026
Trading
Open
$2.71
Previous Close
$2.72
Day's Range
2.66–2.86
52-Week Range
2.81–14.87
Volume
942.24K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.65
Valuation
Market Cap
$226.09M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.07
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$134.04M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
80.17M
1-Year Return
−75.68%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
468.96K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BBOT closed at $2.68, −75.68% over 1 year.

BridgeBio Oncology Therapeutics, Inc. (BBOT) has a market capitalization of $226.09M.

In fiscal 2025, BBOT reported revenue of $0.00.

BBOT Stock Return by Calendar Year

BridgeBio Oncology Therapeutics, Inc. (BBOT) return since Feb 2024: what $10,000 became

1 year
$10,000 $2,432
−75.68%
Since Feb 2024
$10,000 $2,630
−73.70%

If you had invested $10,000 in BridgeBio Oncology Therapeutics, Inc. (BBOT) at the close on February 9, 2024, the earliest close on record here, it would have been worth $2,630 at the close on October 21, 2026: −73.70% in total, −39.06% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−78.59%
2025+19.24%
2024 (partial year)+3.04%

As of October 21, 2026.

BBOT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$134.04M—
2024$0.00−$74.28M—
2023$0.00−$64.70M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$145.82M−$134.04M—
2024$0.00—−$80.86M−$74.28M—
2023$0.00—−$64.77M−$64.70M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BridgeBio Oncology Therapeutics, Inc. (BBOT) carries a market capitalisation of $226.09M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 88 employees.

Over the past 52 weeks the price has ranged from $2.81 to $14.87. The most recent close on file for BBOT is $2.68, dated October 21, 2026. That is −$0.04 (−1.47%) against the previous close.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $134.04M. Trailing earnings per share are −0.07.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $0.00 in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.65. Daily returns over the trailing 2 years annualize to a volatility of 57.71%. Over the trailing twelve months the total return is −75.68%. The stored price history starts on February 9, 2024, and the total return since then is −73.70%.

Growth & Income

The record shows no dividend for BBOT.

The record holds one complete calendar year, 2025, which returned +19.24%. So far in 2026 the total return is −78.59%.

Peer Comparison

BridgeBio Oncology Therapeutics, Inc. (BBOT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BridgeBio Oncology Therapeutics, Inc. BBOT $226.09M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. BridgeBio Oncology Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Visit website →